CCA
NGM

Catalyst Capital Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Catalyst Capital Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-450
Closed -$7K – 497
2019
Q2 		$7K Buy
+450
New +$6.59K ﹤0.01% 359

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Catalyst Capital Advisors's NGM Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2019, closing a stake of 450 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in NGM in Q2 2019 and held it in 1 quarter. The position peaked at $7K in Q2 2019. 51 funds tracked by Wall St. Rank hold NGM as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 450 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $7K in Q2 2019.
  • 51 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.